ERBB2 and neoplasm: Our findings enlarge the panel of LRIG1 targets to 10 RTK members including EGFR, ErbB2, ErbB3, ErbB4, Met, Ret, Ron, PDGFRα, IGF1R14,38 and AXL, non-TK receptors,39 and tumor-specific RTKs such as EGFRvIII.